The main objective of this pilot study is to evaluate the effects of the Brazilian Cardioprotective Diet (DICA Br) supplemented or not with phytosterols and/or krill oil in patients with a probable or definitive diagnosis of familial hypercholesterolemia (FH) identified by the Dutch Lipid Clinic Network (Dutch MEDPED) criteria. In addition, the following will be considered secondary objectives: to perform participants´ complete sequencing of the exome; to evaluate the effects of the interventions on lipid profile; to identify subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol; to perform untargeted lipidomic analyses; to evaluate the frequency of mild, moderate and severe adverse events according to study groups; and to evaluate both implementation components and adherence rates to the protocol, aiming to design a larger randomized trial. In this pilot study, between 48 and 76 individuals will be randomly enrolled into four groups: 1) DICA Br adapted to FH (DICA-HF) + phytosterol placebo + krill oil placebo (control group); 2) DICA-HF + 2g/day of phytosterol + krill oil placebo; 3) DICA-HF + phytosterol placebo + 2g/day of krill oil; and 4) DICA-HF + 2g/day of phytosterol + 2g/day of krill oil. Primary outcomes will be LDL-cholesterol for groups phytosterol vs. placebo and lipoprotein(a) for groups krill oil vs. placebo after 120 days of follow up. World Health Organization Universal Trial Number (WHO-UTN): U1111-1296-7102
DICA-HF pilot study is a superiority, factorial, and in parallel randomized placebo-controlled (double-dummy) clinical trial. The randomization will be in blocks of varying sizes stratified by research center, and the allocation ratio will be 1:1:1:1. Participants will come from at least 9 center sites in different Brazilian geographic regions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
58
2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
Placebo of phytosterol, in the same quantity of the active phytosterol
Placebo of krill oil, in the same quantity of the active krill oil
Hospital São José
Criciúma, Brazil
Hospital das Clínicas da Universidade Federal de Goiás
Goiânia, Brazil
Universidade Regional do Noroeste do Estado do Rio Grande do Sul
Ijuí, Brazil
Instituto Nacional de Cardiologia
Rio de Janeiro, Brazil
Hospital Ana Nery
Salvador, Brazil
Universidade Feevale
São Leopoldo, Brazil
Hcor
São Paulo, Brazil
InCor
São Paulo, Brazil
Instituto Dante Pazzanese de Cardiologia
São Paulo, Brazil
LDL-c
Low-density lipoprotein cholesterol, in mg/dL
Time frame: 120 days
Lp(a)
Lipoprotein(a), in mg/dL
Time frame: 120 days
Adherence
Adherence to treatment, evaluated by: attendance at consultations (at least 3 of the 4 planned study visits); plasma concentrations of phytosterols and erythrocyte levels of EPA/DHA fatty acids (identified by the difference between the last and the first study visits); and counting the consumed products under investigation (consumption of at least 80% of the capsules provided to the participants, regardless of the allocation group).
Time frame: 120 days
TC
Total cholesterol, in mg/dL
Time frame: 120 days
HDL-c
High density lipoprotein cholesterol, in mg/dL
Time frame: 120 days
TG
Fasting triglycerides, in mg/dL
Time frame: 120 days
VLDL
Very low-density lipoprotein cholesterol, in mg/dL
Time frame: 120 days
NHDL
Non-HDL cholesterol, in mg/dL, calculated according to the mathematical formula: CT - HDL-c
Time frame: 120 days
CI I
Castelli Index I, in mg/dL, calculated according to the mathematical formula: CT/HDL-c
Time frame: 120 days
CI II
Castelli Index II, in mg/dL, calculated according to the mathematical formula: LDL-c/HDL-c
Time frame: 120 days
TG/HDL-c
TG/HDL-c ratio, in mg/dL, calculated according to the mathematical formula: TG/HDL-c
Time frame: 120 days
AI
Atherogenic index, in mg/dL, calculated according to the mathematical formula: NHDL/HDL-c
Time frame: 120 days
ox-LDL
Oxidized LDL, in µg/mL
Time frame: 120 days
AE
Adverse events (mild, moderate and severe), registered as percentage per study group
Time frame: 120 days
Implementation
Implementation components, measured by: on-time recruitment rates; choice and adjustments of remote platform/media for center sites training; measures of participants´ engagement to interventions; and rates of loss to follow-up.
Time frame: 120 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.